The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients-Reference-Cited by-同舟云学术

The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients

Published:2021-09 Issue: Volume:155 Page:268-280
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Zaremba Anne,Eggermont Alexander M.M.,Robert Caroline,Dummer Reinhardt,Ugurel Selma,Livingstone Elisabeth,Ascierto Paolo A.^ORCID,Long Georgina V.,Schadendorf Dirk^ORCID,Zimmer Lisa

Funder

Bristol-Myers Squibb

Meso Scale Diagnostics

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019;Ugurel;Eur J Cancer,2020

2. The concepts of rechallenge and retreatment in melanoma: a proposal for consensus definitions;Gebhardt;Eur J Cancer,2020

3. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - Update 2019;Garbe;Eur J Cancer,2020

4. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma;Robert;Eur J Cancer,2019

5. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma;Ascierto;Eur J Cancer,2020

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects;Critical Reviews in Oncology/Hematology;2024-09

3. Rechallenge de l’immunothérapie par nivolumab pour un cancer épidermoïde du larynx en poursuite évolutive après échec des modalités conventionnelles de traitement : cas clinique CARE;Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale;2024-09

4. Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report;European Annals of Otorhinolaryngology, Head and Neck Diseases;2024-08

5. Changes in mucosa‑associated lymphoid tissue 1 predicts therapeutic response and survival in patients with advanced melanoma receiving programmed cell death‑1 inhibitor monotherapy;Oncology Letters;2024-07-12